- Home
- NRO vs ABOS Comparison
NRO vs ABOS Comparison
Compare NRO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- ABOS
- Stock Information
- Founded
- NRO 2003
- ABOS 1996
- Country
- NRO United States
- ABOS United States
- Employees
- NRO N/A
- ABOS N/A
- Industry
- NRO Finance/Investors Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- ABOS Health Care
- Exchange
- NRO Nasdaq
- ABOS Nasdaq
- Market Cap
- NRO 187.8M
- ABOS 171.8M
- IPO Year
- NRO N/A
- ABOS 2021
- Fundamental
- Price
- NRO $3.75
- ABOS $2.40
- Analyst Decision
- NRO
- ABOS Strong Buy
- Analyst Count
- NRO 0
- ABOS 4
- Target Price
- NRO N/A
- ABOS $9.00
- AVG Volume (30 Days)
- NRO 239.4K
- ABOS 207.8K
- Earning Date
- NRO 01-01-0001
- ABOS 11-12-2024
- Dividend Yield
- NRO 11.41%
- ABOS N/A
- EPS Growth
- NRO N/A
- ABOS N/A
- EPS
- NRO N/A
- ABOS N/A
- Revenue
- NRO N/A
- ABOS N/A
- Revenue This Year
- NRO N/A
- ABOS N/A
- Revenue Next Year
- NRO N/A
- ABOS N/A
- P/E Ratio
- NRO N/A
- ABOS N/A
- Revenue Growth
- NRO N/A
- ABOS N/A
- 52 Week Low
- NRO $2.51
- ABOS $2.08
- 52 Week High
- NRO $3.45
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- NRO 35.09
- ABOS 38.88
- Support Level
- NRO $3.77
- ABOS $2.85
- Resistance Level
- NRO $3.98
- ABOS $3.36
- Average True Range (ATR)
- NRO 0.08
- ABOS 0.25
- MACD
- NRO -0.01
- ABOS -0.08
- Stochastic Oscillator
- NRO 3.70
- ABOS 3.03
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.